Clinician's Guide to Preparing and Administering Long-Acting Injectable Antipsychotics-Presentation Slides

Presentation Slides

Pdf Summary

The document is a clinician's guide to preparing and administering long-acting injectable antipsychotic (LAIs) medications. It is part of the Clinical Support System for Serious Mental Illness (CSS-SMI) initiative implemented by the American Psychiatric Association (APA) and funded by the Substance Abuse and Mental Health Services Administration (SAMHSA). The guide provides information on strategies for discussing LAIs with patients, compares available LAIs in terms of treatment considerations and side effects, and demonstrates proper administration techniques.<br /><br />The guide emphasizes the importance of early preparation and negotiation with patients regarding LAIs. It suggests starting the conversation about LAIs early in treatment and explains the benefits, such as reducing the risk of relapse, decreasing intrafamily conflict, and providing more consistent medication levels. It also addresses clinician beliefs and willingness to prescribe LAIs, barriers to their use, and factors influencing clinician prescribing decisions.<br /><br />The document highlights that LAIs decrease the risk of relapse and overall mortality among patients with schizophrenia. It states that LAIs, particularly clozapine and depot preparations, are more effective in preventing hospitalization than oral drugs. LAIs also have a similar side effect profile to their corresponding oral formulations.<br /><br />The guide provides detailed information on the administration of LAIs, including injection site selection, anatomical landmarks, needle size, and injection techniques. It emphasizes the importance of site rotation to avoid complications and recommends post-injection site care, reporting any adverse reactions, and observing patients after Zyprexa Relprevv injections due to the risk of post-injection delirium/sedation syndrome.<br /><br />The document also includes monitoring guidelines for LAIs, such as vital signs, body weight, glucose and lipid levels, and assessment for side effects or movement disorders. It refers to the American Psychiatric Association's practice guidelines for the treatment of patients with schizophrenia and provides additional resources for further information and education on LAIs.<br /><br />Overall, the guide aims to support clinicians in the preparation, administration, and monitoring of LAIs, promoting their effective use in the treatment of serious mental illnesses like schizophrenia.

Keywords

Long-acting injectable antipsychotic medications

Clinical Support System for Serious Mental Illness

American Psychiatric Association

Substance Abuse and Mental Health Services Administration

LAIs administration techniques

Discussing LAIs with patients

Benefits of LAIs in reducing relapse risk

Comparison of available LAIs

Barriers to LAIs use

Monitoring guidelines for LAIs